نتائج البحث - "Adnan Khattak"

1

BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?

المؤلفون: Jeanne Tie, Jayesh Desai, Simone Steel, Vanessa Wong, Jeremy Shapiro, Margaret Lee, Peter Gibbs, Adnan Khattak, Rachel Wong, Wei Hong, Matthew Burge, Brigette B.Y. Ma, Louise M. Nott

المصدر: Targeted Oncology. 16:227-236

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::22f7d7e129140a629988bd9957af1d94Test
https://doi.org/10.1007/s11523-021-00793-7Test

2

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test

3

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

المؤلفون: Adnan Khattak, Hendrik Koffijberg, Belinda Lee, Desmond Yip, Jeremy D. Shapiro, Rachel Wong, Koen Degeling, Louise M. Nott, Peter Gibbs, Maarten Joost IJzerman, Matthew Burge, Jeanne Tie, Hui-Li Wong, Stephanie H Lim, Suzanne Kosmider, Azim Jalali, Susan Caird

المساهمون: Health Services Management & Organisation (HSMO), Erasmus School of Health Policy & Management, Health Technology & Services Research, TechMed Centre

المصدر: PharmacoEconomics, 38(11), 1263-1275. Adis
PharmacoEconomics, 38(11), 1263-1275. Adis International Ltd

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb03024db52ddca17282749a2adf58eTest
https://pubmed.ncbi.nlm.nih.gov/32803720Test

4

Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status

المصدر: Clinical colorectal cancer. 20(1)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Time Factors, Adolescent, Colorectal cancer, Population, Kaplan-Meier Estimate, Systemic therapy, Risk Assessment, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Registries, Karnofsky Performance Status, education, Colectomy, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, Proportional hazards model, business.industry, Gastroenterology, Middle Aged, medicine.disease, Comorbidity, Progression-Free Survival, Oxaliplatin, Tumor Burden, Clinical trial, Oncology, Fluorouracil, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, business, Colorectal Neoplasms, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb92697007a2d9518b81a76a5b5473aTest
https://pubmed.ncbi.nlm.nih.gov/32919889Test

5

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

المؤلفون: Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf, Gabriela Cinat, Luis Enrique Fein, Michael Brown, Andrew Haydon, Adnan Khattak, Catriona McNeil, Phillip Parente, Jeremy Power, Rachel Roberts-Thomson, Shahneen Sandhu, Craig Underhill, Suresh Varma, Thomas Berger, Ahmad Awada, Nathalie Blockx, Veronique Buyse, Jeroen Mebis, Fábio André Franke, Sérgio Jobim de Azevedo, Nicolas Silva Lazaretti, Rahima Jamal, Catalin Mihalcioiu, Teresa Petrella, Kerry Savage, Xinni Song, Ralph Wong, Nina Dabelic, Stjepko Plestina, Zeljko Vojnovic, Petr Arenberger, Ivo Kocak, Ivana Krajsova, Eugen Kubala, Bohuslav Melichar, Yvetta Vantuchova, Kadri Putnik, Brigitte Dreno, Caroline Dutriaux, Jean-Jacques Grob, Pascal Joly, Jean-Philippe Lacour, Nicolas Meyer, Laurent Mortier, Luc Thomas, Michael Fluck, Thilo Gambichler, Jessica Hassel, Axel Hauschild, Paul Donnellan, John McCaffrey, Derek Power, Samuel Ariad, Gil Bar-Sela, Daniel Hendler, Ilan Ron, Jacob Schachter, Paolo Ascierto, Alfredo Berruti, Luca Bianchi, Vanna Chiarion Sileni, Francesco Cognetti, Riccardo Danielli, Anna Maria Di Giacomo, Luca Gianni, Aron Goldhirsch, Michele Guida, Paolo Marchetti, Paola Queirolo, Armando Santoro, Ellen Kapiteijn, Paula Ferreira, Georgy Gafton, Yulia Makarova, Zoran Andric, Nada Babovic, Darjana Jovanovic, Lidija Kandolf Sekulovic, Graham Cohen, Lydia Dreosti, Daniel Vorobiof, Maria Teresa Curiel Garcia, Roberto Diaz Beveridge, Margarita Majem Tarruella, Ivan Marquez Rodas, Jose-M Puliats Rodriguez, Antonio Rueda Dominguez, Marianne Maroti, Karin Papworth, Olivier Michielin, Ewan Brown, Pippa Corrie, Mark Harries, Satish Kumar, Agustin Martin-Clavijo, Mark Middleton, Poulam Patel, Toby Talbot, Sanjiv Agarwala, Paul Chapman, Robert Conry, Gary Doolittle, Tara Gangadhar, Sigrun Hallmeyer, Omid Hamid, Leonel Hernandez-Aya, Douglas Johnson, Frederic Kass, Tatjana Kolevska, Scott Lunin, April Salama, Branimir Sikic, Bradley Somer, David Spigel, Eric Whitman

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ca377ad3c682462789b57095f06c16Test
http://hdl.handle.net/11379/501841Test

6

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

المساهمون: Universitat de Barcelona, Medical oncology, CCA - Cancer Treatment and quality of life

المصدر: Recercat. Dipósit de la Recerca de Catalunya
instname
The New England Journal of Medicine, 378, 1789-1801
New England Journal of Medicine, 378(19), 1789-1801. Massachussetts Medical Society
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Maio, M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P, Ibrahim, N, Marreaud, S, van Akkooi, A C J, Suciu, S & Robert, C 2018, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma ', New England Journal of Medicine, vol. 378, no. 19, pp. 1789-1801 . https://doi.org/10.1056/NEJMoa1802357Test
Dipòsit Digital de la UB
Universidad de Barcelona
The New England Journal of Medicine, 378, 19, pp. 1789-1801

مصطلحات موضوعية: 0301 basic medicine, Male, Skin Neoplasms, Medizin, Pembrolizumab, Kaplan-Meier Estimate, Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, Double-Blind Method, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Survival Rate, Gastroenterology, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Immunologic, Monoclonal, 80 and over, Humanized, Adjuvant treatment of cancer, education.field_of_study, General Medicine, Local, 030220 oncology & carcinogenesis, Intravenous, medicine.drug, Tractament adjuvant del càncer, medicine.medical_specialty, Infusions, Population, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, Adjuvants, education, Survival rate, business.industry, Cancer, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Cutaneous melanoma, business, Placebos (Medicine)